These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1210 related articles for article (PubMed ID: 27629931)

  • 1. Targeting the cancer epigenome for therapy.
    Jones PA; Issa JP; Baylin S
    Nat Rev Genet; 2016 Sep; 17(10):630-41. PubMed ID: 27629931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
    Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
    Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma.
    Hassler MR; Schiefer AI; Egger G
    Epigenomics; 2013 Aug; 5(4):397-415. PubMed ID: 23895653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment "jigsaw puzzle".
    Dzobo K
    OMICS; 2019 Feb; 23(2):70-85. PubMed ID: 30767728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA demethylating agents and epigenetic therapy of cancer.
    Mani S; Herceg Z
    Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors.
    Kumar A; Emdad L; Fisher PB; Das SK
    Adv Cancer Res; 2023; 158():73-161. PubMed ID: 36990539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological targeting of the cancer epigenome.
    Mabe NW; Perry JA; Malone CF; Stegmaier K
    Nat Cancer; 2024 Jun; 5(6):844-865. PubMed ID: 38937652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction into the analysis of high-throughput-sequencing based epigenome data.
    Huss M
    Brief Bioinform; 2010 Sep; 11(5):512-23. PubMed ID: 20457755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
    Rondelet G; Wouters J
    Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetics and oncology.
    Mummaneni P; Shord SS
    Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenome-based personalized medicine in human cancer.
    Yan W; Herman JG; Guo M
    Epigenomics; 2016 Jan; 8(1):119-33. PubMed ID: 26344672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Chromatin Remodeling for Cancer Therapy.
    Kaur J; Daoud A; Eblen ST
    Curr Mol Pharmacol; 2019; 12(3):215-229. PubMed ID: 30767757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compendium of aberrant DNA methylation and histone modifications in cancer.
    Hattori N; Ushijima T
    Biochem Biophys Res Commun; 2014 Dec; 455(1-2):3-9. PubMed ID: 25194808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current paradigms in epigenetic anticancer therapeutics and future challenges.
    Singh M; Kumar V; Sehrawat N; Yadav M; Chaudhary M; Upadhyay SK; Kumar S; Sharma V; Kumar S; Dilbaghi N; Sharma AK
    Semin Cancer Biol; 2022 Aug; 83():422-440. PubMed ID: 33766649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
    Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
    Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling epigenetic alterations in disease.
    Martín-Subero JI; Esteller M
    Adv Exp Med Biol; 2011; 711():162-77. PubMed ID: 21627049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.
    Brien GL; Valerio DG; Armstrong SA
    Cancer Cell; 2016 Apr; 29(4):464-476. PubMed ID: 27070701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promises and challenges of anticancer drugs that target the epigenome.
    Verbrugge I; Johnstone RW; Bots M
    Epigenomics; 2011 Oct; 3(5):547-65. PubMed ID: 22126246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.